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REVIEW
Abstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses
of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil
was significantly more effective than placebo in terms of the response rate, proportion of
patients achieving target blood pressure (BP) and mean change from baseline in diastolic
(DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action,
with significant between-group differences evident from 2 weeks onwards. The drug was
well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes,
olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and
reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan
medoxomil 20 mg has been shown to be significantly more effective, in terms of primary
endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil,
and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as
amlodipine, felodipine and atenolol, and significantly more effective than captopril. The
efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is
currently being investigated in trials involving patients at high risk due to atherosclerosis or
type 2 diabetes.
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Introduction
Individuals with hypertension are at a significantly greater risk of morbidity and
mortality from cardiovascular disease. The largest study of the effects of hypertension
on cardiovascular risk comes from analysis of data from more than one million adults
who had no known baseline cardiovascular disease. This meta-analysis revealed a
linear relationship between cardiovascular risk and increasing systolic blood pressure
(SBP) in which each increase of 20 mmHg in SBP was associated with a doubling of
cardiovascular risk in patients aged 40–60 (Lewington et al 2002). More recently,
the INTERHEART study has demonstrated that hypertension is one of the most potent
predictors of myocardial infarction (Yusuf et al 2004).
The benefits of BP reduction in reducing morbidity and mortality in conditions
associated with hypertension have been clearly shown. In clinical trials, treating
hypertension reduced the incidence of stroke by 35%–40%, myocardial infarction
by 20%–25%, and heart failure by >50% (Chobanian et al 2003). Thus, in patients
with uncomplicated hypertension, the minimal goal of therapy is a systolic blood
pressure (SBP) of <140 mmHg and a diastolic blood pressure (DBP) of <90 mmHg
(Chobanian et al 2003) or <80 mmHg (ESH–ESC 2003). In hypertensive patients
with diabetes or renal disease, the goals are <80 mmHg and <130 mmHg.
Angiotensin II is a potent vasoconstrictor and the primary effector of the renin–
angiotensin system (RAS), which plays a central role in the regulation of BP (Brunner
et al 1993). Evidence suggests that increased angiotensin II levels are an independent
risk factor for cardiac disease (Brunner 2001). Thus, the development of treatments
like angiotensin-converting enzyme (ACE) inhibitors, which inhibit the activity of
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the RAS, provided an effective approach to the treatment
of hypertension. However, ACE inhibitors are associated
with various adverse effects such as cough and angioedema
(Fletcher et al 1994; Vleeming et al 1998) and further
research and clinical development has led to the
development of highly specific angiotensin II receptor
antagonists.
Angiotensin II receptor antagonists inhibit the RAS at
the level of the angiotensin II type 1 receptor, thereby
providing effective antihypertensive efficacy without the
side effects associated with ACE inhibitors. Angiotensin II
receptor antagonists have proven efficacy in treating
hypertension (Burnier and Brunner 2000), and a tolerability
profile similar to placebo (Mazzolai and Burnier 1999).
Furthermore, the initial use of one of these agents has been
shown to increase long-term patient persistence rates
compared with those for patients initially prescribed ACE
inhibitors, calcium channel antagonists, beta-blockers, or
thiazide diuretics (Conlin et al 2001).
Olmesartan medoxomil is a nonpeptide angiotensin II
receptor antagonist that selectively and competitively
inhibits the type 1 angiotensin II receptor (Mizuno et al
1995). Olmesartan medoxomil is administered once daily
for the treatment of hypertension (Nussberger and Koike
2004). The agent has low potential for interaction with other
drugs, and has been shown to be at least as effective as a
number of other commonly used antihypertensive drugs.
This article reviews the use of olmesartan medoxomil as
monotherapy in patients with hypertension.
Pharmacological properties
Pharmacodynamics
Olmesartan medoxomil is a nonpeptide angiotensin II
receptor antagonist. The drug acts by selectively blocking
angiotensin II type 1 receptor sites in vascular smooth
muscle, thereby inhibiting the vasoconstrictor effects of
angiotensin II. In salt-restricted hypertensive adults, a single
dose of olmesartan medoxomil lowered mean 24 h
ambulatory BP and increased renin and angiotensin II
concentrations in the plasma (Puchler et al 1997).
In bovine cerebellar membranes, olmesartan
competitively inhibited binding of [
125I]-angiotensin II to
angiotensin II type 1 receptors, but not to type 2 receptors
(Mizuno et al. 1995). Olmesartan and the active metabolite
of losartan (EXP3174) both antagonized contraction induced
by angiotensin II in a dose-dependent manner in guinea pig
aortic tissue. However, olmesartan medoxomil 0.3 nmol/L
inhibited approximately 90% of the contractile response,
whereas the same concentration of EXP3174 inhibited
contraction by approximately 35%. The inhibitory effects
of olmesartan and EXP3174 lasted for <90 and <60 minutes,
respectively (Mizuno et al 1995).
In rats, olmesartan medoxomil inhibited the angiotensin
II-induced pressor response (Mizuno et al 1995; Koike et
al 2001), and prevented production of markers of early
cardiovascular inflammation (Usui et al 2000), myocardial
remodeling (Takemoto et al 1997), and cardiac fibrosis
(Tomita et al 1998) induced by inhibition of nitric oxide
synthesis. Olmesartan medoxomil also reduced urinary
protein excretion in a dose-dependent fashion in Zucker
diabetic fatty rats (Koike 2001) and spontaneously
hypertensive rats (Koike et al 2001). In animal models of
atherosclerosis, olmesartan medoxomil has been shown to
reduce the area of aortic plaque lesions and to reduce intimal
thickening in cross sections of the aorta (Koike 2001; Koike
et al 2001).
Pharmacokinetics
Olmesartan medoxomil is a prodrug that is rapidly
hydrolyzed into olmesartan in the gastrointestinal tract.
Olmesartan is rapidly absorbed from the gastrointestinal tract
into the body, with a maximum plasma concentration (Cmax)
of 0.22–2.1 mg/L and time to Cmax of 1.4–2.8 h following
administration of olmesartan medoxomil 10–160 mg
(Schwocho and Masonson 2001). For the same doses, the
mean area under the concentration-time curve (AUC) was
1.6–19.9 mgh/L.
Olmesartan is the only metabolite of olmesartan
medoxomil, and is excreted in the feces (~60%) and the
urine. Following the administration of olmesartan
medoxomil 20 mg to healthy volunteers, the mean terminal
elimination half-life was 12–18 h (Schwocho and Masonson
2001). This relatively long half-life means angiotensin II
type 1 receptor binding can be achieved with once-daily
administration (Wehling 2004), which compares favorably
with the half-lives of some other angiotensin II receptor
antagonists: irbesartan (11–15 h), losartan (2 h) and its active
metabolite (4–5 h), and valsartan (6 h).
Although the AUC increased in elderly patients, and the
AUC and Cmax increased and renal clearance decreased in
patients with renal impairment, dosage adjustment should
not be necessary in elderly patients or those with mild-to-
moderate renal impairment (Brunner 2002).Vascular Health and Risk Management 2006:2(4) 329
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Olmesartan is not metabolized by cytochrome P-450
enzymes and is therefore unlikely to interact with drugs that
inhibit, induce, or are metabolized by cytochrome P-450
enzymes (Wehling 2004). In drug interaction studies, there
were no clinically significant effects on the pharmacokinetic
properties of either drug when olmesartan medoxomil was
coadministered with warfarin, digoxin, or aluminum
magnesium hydroxide (Wehling 2004).
Clinical trials
Placebo-controlled trials
The efficacy of olmesartan medoxomil compared with
placebo in adults with mild-to-moderate essential
hypertension has been reviewed previously in pooled
analyses (Neutel 2001; Puchler et al 2001; Brunner 2004).
These analyses included 7 randomized, double-blind,
multicenter phase II or III trials, conducted in the US or
EU. All studies included placebo run-in periods and were
of a duration of at least 8 weeks. Studied doses ranged from
2.5 mg to 80 mg; this review will focus on the doses
recommended in the EU: 10 mg (starting dose), 20 mg
(optimal dose), and 40 mg (maximum dose). The primary
endpoints were as follows: the proportion of patients
achieving a sitting DBP response (sitting DBP ≥90 mmHg
or reduced by ≤10 mmHg from baseline); the proportion of
patients achieving a target sitting DBP of ≤90 mmHg; and
the change from baseline in mean sitting DBP (Neutel 2001;
Puchler et al 2001). Efficacy analyses included all patients
who received at least one dose of study medication and had
at least one follow-up measurement of any efficacy variable.
A total of 3055 patients were randomized to treatment.
Of these, 544 received placebo and 522, 562, and 195
received olmesartan medoxomil 10 mg, 20 mg, and 40 mg,
respectively. At baseline, the mean sitting DBP and SBP
were approximately 104 mmHg and 160 mmHg (Neutel
2001; Sankyo Pharma GmbH 2002). The mean age of
patients was ~55 years (range 22–92); with the majority of
patients aged <65 years (80%) and Caucasian (87–88%)
(Puchler et al 2001).
After treatment for 8 weeks, olmesartan medoxomil was
significantly more effective than placebo in terms of the
proportion of patients achieving target sitting DBP, and the
mean change from baseline in sitting DBP (Figures 1b, and
1c). Significant differences between olmesartan medoxomil
and placebo in these endpoints were observed from the first
assessment (week 2) onwards (Figures 1b, and 1c) (Sankyo
Pharma GmbH 2002).
The proportions of placebo and olmesartan medoxomil
10 mg, 20 mg, and 40 mg recipients who achieved target
sitting SBP ≤140 mmHg were 20%, 29%, 34%, and 34%
after treatment for 2 weeks (Sankyo Pharma GmbH 2002)
and 20%, 41%, 45%, and 49% after treatment for 8 weeks
(Puchler et al 2001) (p <0.001 vs placebo) (Figure 1a). The
mean reduction in sitting SBP after two weeks was
4.62 mmHg for placebo recipients, compared with
11.55 mmHg, 12.55 mmHg, and 13.08 mmHg for olmesartan
medoxomil 10 mg, 20 mg, and 40 mg recipients (p <0.001)
(Sankyo Pharma GmbH 2002). Respective reductions after
treatment for 8 weeks were 6.76 mmHg compared with
15.99 mmHg, 16.94 mmHg, and 20.65 mmHg (p <0.001)
(Puchler et al 2001).
All doses of olmesartan medoxomil were well tolerated,
with a similar adverse event profile to placebo and no
apparent dose-related trends (Table 1) (Puchler et al. 2001).
The majority of events were mild or moderate in severity.
Seven adverse events were pre-defined as being of special
interest (headache, cough, angioedema, hypotension,
hyperkalemia, gastrointestinal disorders, and liver and
biliary function disorders). The most common adverse event
was headache, which was experienced by more
(numerically) placebo than olmesartan medoxomil recipients
(Table 1). No patients experienced angioedema, while
hypotension and hyperkalemia were very rare (Table 1).
Slightly more olmesartan medoxomil than placebo recipients
Table 1 Tolerability of olmesartan medoxomil 10 mg, 20 mg and
40 mg compared with placebo in a pooled analysis of 7
randomized, double-blind, multicenter trials: percentage of
patients experiencing adverse events (AEs) (Puchler et al 2001)
Olmesartan medoxomil Placebo
10 mg 20 mg 40 mg
(n=528) (n=900) (n=370) (n=555)
Treatment-emergent 49.1 50.6 40.3 47.2
Drug-related
a 21.8 23.7 19.7 22.0
Serious 1.43 1.93 2.12 1.37
Withdrawals
because of AEs 1.9 1.7 1.6 1.1
AEs of special interest
Headache 6.3 6.4 4.3 9.4
Cough 1.5 1.4 0.8 1.1
Hypotension 0.0 0.1 0.0 0.0
Angioedma 0.0 0.0 0.0 0.0
Hyperkalemia 0.0 0.2 0.0 0.0
Gastrointestinal disorders 7.2 8.3 6.5 5.2
Liver and biliary
function disorders 4.0 3.0 2.4 3.6
Note: 
aAt least remotely related to treatment.Vascular Health and Risk Management 2006:2(4) 330
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Figure 1 Efficacy of olmesartan medoxomil (OLM) at 2- (Sankyo Pharma GmbH 2002) and 8- (Puchler et al 2001) weeks in a pooled analysis of 7 placebo-controlled
trials: primary efficacy endpoints.
a) The proportion of patients achieving a target sitting systolic blood pressure ≤140 mmHg
b) The proportion of patients achieving a target sitting dystolic blood pressure (DBP) of ≤90 mmHg.
c) Mean change from baseline in sitting DBP.
Note: *p<0.001
a)
b)
c)Vascular Health and Risk Management 2006:2(4) 331
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experienced gastrointestinal-related disorders, while the
incidence of liver and biliary function disorders was similar
across the groups (Table 1). Other common adverse events
included upper-respiratory tract infection, influenza-like
symptoms, bronchitis, and dizziness, all of which were
experienced by similar proportions of patients in the placebo
and olmesartan medoxomil groups. There were no clinically
significant changes in any of the laboratory variables
assessed.
Target organ protection
In patients with diabetes, increased renal and intra-renal
activity of the RAS can contribute to the development of
diabetic renal damage by increasing renovascular resistance
and intraglomerular pressure. The effects of angiotensin II
receptor blockade on renal hemodynamics in patients with
type 2 diabetes have been studied in a randomized, placebo-
controlled study involving olmesartan. When normotensive
or hypertensive patients with type 2 diabetes received
olmesartan medoxomil 40 mg (n=19) or placebo (n=16) for
12 weeks olmesartan medoxomil decreased renal vascular
resistance, increased renal perfusion and reduced oxidative
stress (Fliser et al 2005). In addition to significantly reducing
mean ambulatory 24 h, daytime, and nighttime DBP and SBP
from baseline, olmesartan medoxomil significantly (p<0.05)
increased renal plasma flow (from 602–628 mL/min/
1.73 m
2) and decreased filtration fraction and renovascular
resistance. Plasma concentrations of 8-isoprostane 15(S)-
8-prostaglandin F2a, a biochemical marker of oxidative
stress, also decreased significantly with olmesartan
medoxomil (p<0.05). In contrast, patients who received
placebo showed no significant effect on BP, a significant
decrease in renal plasma flow and increase in filtration
fraction (p<0.05), and a non-significant increase in
renovascular resistance. In patients with type 2 diabetes,
such changes in renal hemodynamics and oxidative stress
may contribute to the beneficial long-term renal effects of
angiotensin II blockade with agents such as olmesartan
medoxomil.
Patients with hypertension frequently suffer from other
conditions that increase their risk of cardiovascular disease,
such as atherosclerosis. Chronic vascular inflammation is
believed to play a major role in atherosclerosis and the
EUropean Trial on Olmesartan and Pravastatin in
Inflammation and Atherosclerosis (EUTOPIA) set out to
investigate the effects of olmesartan medoxomil 20 mg on
markers of vascular inflammation. In this double-blind,
placebo-controlled multicenter study, patients with essential
hypertension and signs of vascular microinflammation were
randomly allocated to treatment with olmesartan medoxomil
(n=100) or placebo (n=99) for 12 weeks (Fliser et al 2004).
After 6 weeks, all patients also received once-daily
pravastatin 20 mg. After treatment for 6 weeks, olmesartan
medoxomil reduced serum levels of high-sensitivity C-
reactive protein (hsCRP), a strong predictor of
cardiovascular events, by 15% from baseline (p<0.05).
Olmesartan medoxomil also significantly reduced levels of
high-sensitivity tumor necrosis factor-α (hsTNF-α) by 8.9%
(p<0.02), interleukin-6 (IL-6) by 14.0% (p<0.05) and
monocyte chemotactic protein-1 by 6.5% (p<0.01). In
contrast, there were no major changes in the placebo (ie,
BP reduction) group. At the end of the trial, olmesartan
medoxomil plus pravastatin, but not placebo plus
pravastatin, had further reduced levels of hsCRP (21.1%, p
<0.01), hsTNF-α (13.6%, p<0.01), and IL-6 (18.0%,
p<0.01). These anti-inflammatory changes indicate that
olmesartan medoxomil, in addition to its BP-lowering
effects, may produce beneficial effects on atherosclerosis
and thus on overall cardiovascular risk in patients with
hypertension who have atherosclerosis, or are at risk of
developing it.
Comparative trials with
olmesartan medoxomil
Versus other angiotensin II receptor
antagonists
The first study to evaluate the comparative efficacy and
tolerability of olmesartan medoxomil with another
angiotensin II receptor antagonist was a double-blind,
randomized, parallel-group study in which 316 patients with
mild-to-moderate hypertension (DBP 95–114 mmHg) were
treated with either olmesartan medoxomil or losartan for
12 weeks. After 2, 4, and 12 weeks, DBP showed
significantly greater reductions with olmesartan medoxomil
(8.4 mmHg, 9.1 mmHg, 10.6 mmHg, respectively) than with
losartan (6.2 mmHg, 6.4 mmHg, 8.5 mmHg, respectively;
95% confidence index [CI] below zero). The changes in
SBP at these time points were also significantly greater with
olmesartan 10mg once daily (12.1 mmHg, 13.0 mmHg,
14.9 mmHg) than with losartan 50 mg once daily (7.6 mmHg,
9.5 mmHg, 11.6 mmHg, 95% CI below zero). The proportion
of responders (DBP <90 mmHg and/or reduced by
≥10 mmHg from baseline) was also significantly greater with
olmesartan medoxomil than losartan at weeks 2 (45% vs
30%, respectively p<0.01) and 4 (54% vs 32%, respectivelyVascular Health and Risk Management 2006:2(4) 332
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p<0.01), and numerically greater at week 12 (63% vs
52%, respectively) (Stumpe and Ludwig 2002; Stumpe
2004).
The efficacy of olmesartan medoxomil has also been
compared with other angiotensin II receptor antagonists in
two multicenter, randomized, double-blind, parallel-group
trials (Oparil et al 2001; Brunner et al 2003) which had either
a 2- (Brunner et al 2003) or 4-week (Oparil et al 2001)
placebo run-in period before treatment. In the trial reported
by Oparil and colleagues (2001), 588 patients with a mean
cuff DBP of 100–115 mmHg and ambulatory daytime DBP
≥90 mmHg and <120 mmHg were randomized to receive
once-daily olmesartan medoxomil 20 mg or losartan (50 mg),
valsartan (80 mg) or irbesartan (150 mg; at the time that this
study was initiated, these were the recommended starting
doses for each agent) (Oparil et al 2001) After treatment for
8 weeks, olmesartan medoxomil reduced the mean sitting
cuff DBP (primary endpoint) from baseline by significantly
more than losartan, valsartan, or irbesartan (Table 2);
significant between-group differences in this endpoint were
observed from the first assessment point (2 weeks) onwards.
Although olmesartan medoxomil reduced the mean sitting
cuff SBP numerically more than the other agents, these
differences did not reach statistical significance (Table 2).
The mean ambulatory 24 h DBP was reduced significantly
more in the olmesartan medoxomil group than the losartan,
valsartan or irbesartan groups (Table 2). Olmesartan
medoxomil also reduced the mean ambulatory 24 h SBP,
daytime DBP and SBP, and nighttime SBP by significantly
more than losartan or valsartan, and the mean ambulatory
nighttime DBP by significantly more than valsartan (Table
2).
The trial by Brunner and colleagues (2003) compared
once-daily olmesartan medoxomil 20 mg with candesartan
cilexetil 8 mg in 635 patients with a trough mean sitting
DBP of 100–120 mmHg and SBP >150 mmHg after
withdrawal of existing antihypertensive agents (Brunner et
al 2003). After treatment for 8 weeks, olmesartan medoxomil
recipients had a significantly greater reduction from baseline
in mean ambulatory daytime DBP (primary endpoint) than
candesartan cilexetil recipients (Table 2). Olmesartan
medoxomil had an early onset of action; after 1 and 2 weeks
of treatment, the mean decreases in daytime DBP were 72%
and 90% of those observed at 8 weeks, compared with 68%
and 78% with candesartan cilexetil. Olmesartan medoxomil
also reduced mean ambulatory 24 h DBP and daytime SBP
by significantly more than candesartan cilexetil (Table 2).
It should be noted that the dose selection in this comparison
reflected the current recommended maintenance doses
according to product information, at the time of study
development, as required by regulatory authorities for head-
to-head trials.
Table 2 Mean reduction from baseline in cuff and ambulatory blood pressure (mmHg) after 8 weeks of treatment with angiotensin
II receptor blockers in two multicenter, double-blind trails. In the Oparil et al (2001) trial, the mean cuff dystolic blood pressure
(DBP) and systolic blood pressure (SBP) values at baseline were 104 mmHg and 155–157 mmHg. In the Brunner et al (2003) study,
the mean ambulatory daytime DBP and SBP were ≈95 mmHg and ≈149 mmHg at baseline
Oparil et al 2001 Brunner et al 2003
Olmesartan Losartan Valsartan Irbesartan Olmesartan Candesartan
medoxomil medoxomil cilexetil
20 mg 50 mg 80 mg 150 mg 20 mg 8 mg
(n=145) (n=146) (n=142) (n=145) (n=312) (n=323)
Cuff measurements
DBPa 11.5 8.2*** 7.9*** 9.9* 15.8 15.1
SBP 11.3 9.5 8.4 11.0 21.2 21.1
Ambulatory measurements
24 h
DBP 8.5 6.2* 5.6* 7.4* 9.1 7.7*
SBP 12.5 9.0* 8.1* 11.3 12.7 11.0
Day
DBPb 10.2 7.2** 7.0*** 8.8 9.3 7.8*
SBP 14.7 10.9** 10.2** 13.8 13.0 11.1*
Night
DBP 6.8 5.2 4.2** 5.9 7.9 6.7
SBP 10.3 7.3* 6.1** 8.8 10.9 9.7
Note: 
aPrimary endpoint in the trial by Oparil et al (2001); 
bPrimary endpoint in the trial by Brunner et al (2003); *p≤0.05; **p≤0.005; ***p≤0.0005 vs olmesartan
medoxomil.Vascular Health and Risk Management 2006:2(4) 333
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A smaller open-label trial has compared the effects of
once-daily olmesartan medoxomil 20 mg with valsartan
160 mg in 114 patients using ambulatory blood pressure
monitoring (ABPM) with DBP >95 mmHg and <110 mmHg
(Destro et al 2005) After 8 weeks of treatment, both
olmesartan medoxomil and valsartan significantly reduced
mean ambulatory 24 h DBP (by 11.2 mmHg and 12.2 mmHg,
respectively) and SBP (14.6 mmHg and 15.7 mmHg,
respectively), daytime DBP (11.8 mmHg and 12.7 mmHg,
respectively) and SBP (15.0 mmHg and 16.0 mmHg,
respectively), and nighttime DBP (9.7 mmHg and
10.8 mmHg) and SBP (13.7 mmHg and 14.5 mmHg) from
baseline (p<0.001). It should be noted that these results were
achieved with a relatively high dose of valsartan. In Europe,
the recommended dose is 80 mg, with higher doses
recommended for patients who require further BP lowering.
Versus a calcium channel blocker
In two multicenter, randomized, parallel-group trials with
placebo run-in periods, olmesartan medoxomil 20 mg was
compared with the calcium channel blockers amlodipine
5 mg (Chrysant et al 2003) and felodipine 5 mg (Stumpe
and Ludwig 2002) in patients with mild-to-moderate
hypertension.
When the trial comparing olmesartan medoxomil with
amlodipine was published (Chrysant et al 2003), amlodipine
was the most widely prescribed antihypertensive agent for
patients with mild-to-moderate hypertension. In this trial,
440 patients were randomized 3:3:1 to one of the active
treatments or placebo. After treatment for 8 weeks,
olmesartan medoxomil and amlodipine both reduced mean
24 h ambulatory DBP (primary endpoint) and SBP from
baseline by significantly (p<0.001) more than placebo (DBP
7.7 mmHg and 7.0 mmHg vs 1.4 mmHg; SBP 12.2 mmHg
and 12.3 mmHg vs 2.3 mmHg). Ninety percent CI comparing
the mean change between olmesartan and amlodipine were
−1.88, 0.47 and −1.96, 1.96, for 24 h DBP and SBP,
respectively. Control rates of mean 24 h DBP <85 mmHg
and SBP <130 mmHg were assessed, olmesartan medoxomil
was significantly (p≤0.01) superior to both amlodipine and
placebo. Using these criteria, for the olmesartan medoxomil,
amlodipine and placebo groups the 24 h ambulatory control
rates were 48.0%, 34.3%, and 11.1% (DBP) and 33.9%,
17.4%, and 3.7% (SBP), respectively. Absolute differences
between the 90% CI Both agents were well tolerated; the
overall incidence of treatment-emergent adverse events did
not differ significantly among the three groups (25.8%–
35.5%), and most adverse events were mild or moderate in
severity and judged to be remotely or definitely not related
to treatment. As would be expected from the established
tolerability profile of amlodipine, the incidence of edema
was higher in the amlodipine group (9.1%) than the
olmesartan medoxomil (4.3%) or placebo (4.5%) groups,
as was the incidence of nausea (2.7%, 0%, and 0%). It should
be noted that at the time of study design development target
DBP <85 mmHg was considered clinically appropriate.
In the other trial, 187 patients received olmesartan
medoxomil 20 mg once daily and 194 received felodipine
5 mg once daily (Stumpe and Ludwig 2002). The dose of
each medication could be doubled for non-responders after
4 weeks. After treatment for 12 weeks, there was no
significant difference between olmesartan medoxomil and
felodipine in reductions from baseline for mean sitting DBP
(17.5 mmHg and 17.0 mmHg) and SBP (19.9 mmHg and
19.1 mmHg). The responder rates were 82.8% for olmesartan
medoxomil and 83.3% for felodipine. Both agents were well
tolerated; however, as expected, the incidence of edema was
higher with felodipine (2.6%) than olmesartan (0%).
Versus an angiotensin-converting
enzyme inhibitor
Olmesartan medoxomil 5 mg once daily was compared with
captopril 12.5 mg twice daily in 291 patients with mild-to-
moderate hypertension (mean sitting DBP 95–114 mmHg)
in a multicenter, randomized, double-blind trial (Williams
2001; Stumpe and Ludwig 2002). The dose of either
medication could be doubled after 4 weeks and again after
8 weeks for non-responders. After 12 weeks, olmesartan
medoxomil reduced mean sitting DBP and SBP from
baseline by significantly more than captopril (9.9 mmHg vs
6.8 mmHg, 95% CI 4.8, 1.5 [DBP]; 14.7 mmHg vs
7.1 mmHg, 95% CI 10.4, 4.7 [SBP]). Additionally, the
response rate was significantly higher for olmesartan
medoxomil recipients (53% vs 38%, p<0.01). The average
final dose for olmesartan medoxomil was 10.4 mg once daily
(41.7% of patients were on the 5 mg dose) and for captopril
was 37.0 mg twice daily (54.9% of patients on the 50 mg
dose) after 12 weeks.
Versus a beta-blocker
In a double-blind study, 326 patients with mild-to-moderate
hypertension (mean sitting DBP 95–114 mmHg) were
randomized to receive once-daily olmesartan medoxomil
10 mg or atenolol 50 mg for 12 weeks; after 4 weeks, the
dose of either medication could be doubled for non-
responders (Van Mieghem 2001; Stumpe and Ludwig 2002).Vascular Health and Risk Management 2006:2(4) 334
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After treatment for 12 weeks, both olmesartan medoxomil
and atenolol reduced mean sitting DBP from baseline by a
similar amount (14.2 mmHg and 13.9 mmHg), whereas
olmesartan medoxomil reduced mean sitting SBP by
significantly more than atenolol (21.2 mmHg vs 17.1 mmHg,
95% CI 6.6, 1.6).
Recent, forthcoming and ongoing
studies with olmesartan medoxomil
The OLMesartan: reduction of Blood Pressure in the
treatment of patients suffering from mild-to-moderate
ESentTial hypertension (OlmeBEST) study is a recent
multinational, parallel group, partially-randomised double-
blind study which involved more than 1600 patients with
hypertension from Austria, Belgium, Germany, the
Netherlands, and the UK. After a 2-week placebo run-in,
patients received olmesartan medoxomil 20 mg/day open
label for 8 weeks. After this, patients who did not achieve a
DBP of <90 mmHg were randomised to 4 weeks of treatment
with olmesartan medoxomil 40 mg/day or olmesartan
medoxomil 20 mg/day plus hydrochlorothiazide 12.5 mg/
day. Interim results from Germany (n=823) for the open label
phase showed that DBP and SBP had been reduced by
11.8 mmHg and 17.1 mmHg, respectively (Ewald et al 2005).
Renin–angiotensin blockade
It has been shown that certain angiotensin receptor blockers
(ARBs), including losartan and valsartan, do not produce
complete 24 h receptor blockade at their recommended doses
(Maillard et al 2002). Combining an ACE inhibitor with an
ARB could be used to prolong and increase RAS blockade.
However, such an approach would of course expose patients
to the risk of ACE inhibitor-associated side effects such as
cough.
A recent double-blind cross-over study in healthy
normotensive males investigated the effects of RAS
blockade with the olmesartan medoxomil 20 mg, 40 mg and
80 mg, and compared this with the ACE inhibitor lisinopril
20 mg alone, or combined with olmesartan medoxomil
20 mg or 40 mg. The primary end-point was the degree of
RAS blockade as assessed by SBP response to intravenously
administered angiotensin I. At trough, the SBP response was
58% to either lisinopril 20 mg or olmesartan medoxomil
20 mg, 76% to olmesartan 80 mg and 80% to olmesartan
medoxomil 20 mg plus lisinopril 20 mg. Thus, the 80 mg
dose of olmesartan medoxomil was as effective as a lower
dose combined with an ACE inhibitor (Hasler et al 2005).
This shows that using a higher dose of olmesartan
medoxomil can produce an almost complete 24 h RAS
blockade. Such a treatment strategy is preferable since it
would of course be free from the side effect concerns
associated with the use of an ACE inhibitor.
General practice
Patients with hypertension usually respond well to
appropriate intervention in the setting of controlled clinical
trials. However, the situation in general practice is less
certain and issues such as compliance and the lower
frequency of patient–physician meetings have the potential
to reduce the efficacy of treatment. In this context, two
studies have assessed the efficacy and tolerability of
olmesartan medoxomil in patients with hypertension in a
general practice situation.
The OlmePAS study enrolled more than 12 000 patients
in Germany. Physicians in more than 3400 clinical practices
were involved in the study. The initial results indicate that
olmesartan 20 mg was the most frequently prescribed dose
and that after 12 weeks of treatment the mean decrease from
baseline was 28.4 mmHg SBP and 14.2 mmHg for DBP
(Scholze and Ewald 2005). The OlmeTEL study (Olmetec
zur Behandlung von Patienten mit essentialler Hypertonie.
Telemonitoring Blutdruck) (n=53) assessed the feasibility
of using BP self-monitoring (BPSM) to monitor treatment
with olmesartan medoxomil in a study carried out in 27
clinical practices in Germany. The median dose of
olmesartan medoxomil was 20 mg, and after 12 weeks,
decreases from baseline of 27.6 mmHg and 16.0 mmHg were
seen in office SBP and DBP, respectively (Mengden et al
2004). Thus, in a general practice setting, olmesartan
medoxomil produces BP reductions that are of a similar
magnitude to those seen in controlled clinical studies.
24 hour blood pressure control
BP shows a natural diurnal variation in both normotensive
and hypertensive individuals (Muller et al 1985). During
the early morning there is a ‘surge’ in BP which has been
shown to coincide with an increase in the rate of
cardiovascular events, including myocardial infarction and
sudden cardiac death (Cohen et al 1997). Blood pressure
measurement using ABPM enables the efficacy of
antihypertensive treatments to be assessed throughout the
whole of a 24 h dosing period. This method of assessing
antihypertensive efficacy was used in the comparative
studies by Oparil and colleagues (2001) and Brunner and
colleagues (2003). A recent post-hoc analysis of the resultsVascular Health and Risk Management 2006:2(4) 335
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reported by Oparil and colleages (2001) showed that the
mean reductions from baseline after 8 weeks with olmesartan
medoxomil 20 mg were greater than those with valsartan
80 mg for SBP and DBP for all dosing periods analysed
(Figure 2). These periods included the whole of the 24 h
dosing period, daytime and night-time periods and the last
4 h and 2 h of ABPM, which is the time associated with the
early morning ‘surge’ in BP. The reductions from baseline
with olmesartan medoxomil were also greater than those
seen with losartan 50 mg for SBP for all dosing periods
analysed and were numerically greater than those produced
by irbesartan 150 mg (Smith et al 2005). A similar post-hoc
analysis of the study reported by Brunner et al. also showed
that olmesartan medoxomil provided BP control over 24 h
in terms of the proportions of patients achieving ABPM
goals and larger decreases from baseline during the last 4 h
and 2 h of ABPM (Brunner and Arakawa 2005).
Target organ protection
Type 2 diabetes is strongly associated with hypertension
and kidney damage. The first clinically detectable sign of
renal disease is microalbuminuria which is a predictor for
nephropathy as well as cardiovascular disease (Mogensen
2002). Studies have shown that angiotensin II receptor
antagonists have renoprotective effects in diabetes (Brenner
et al 2001; Lewis et al 2001) and can slow the progression
of microalbuminuria (Parving et al 2001). However, what
is not known is whether the development of
microalbuminuria can be prevented or slowed by an
angiotensin II receptor antagonist.
The Randomised Olmesartan And Diabetes
MicroAlbuminuria Prevention (ROADMAP) study is the
first large-scale, randomised, placebo-controlled, double-
blind primary prevention trial which specifically aims to
determine whether olmesartan medoxomil 40mg daily can
Figure 2 Hourly mean change in SBP and DBP by ABPM from baseline to the end of 8 weeks of treatment with olmesartan medoxomil 20 mg/day or valsartan
80 mg/day, with the early morning period indicated (Smith et al 2005).
Abbreviations: ABPM, ambulatory blood pressure monitoring; DBP, dystolic blood pressure; SBP, systolic blood pressure.Vascular Health and Risk Management 2006:2(4) 336
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prevent or delay the onset of microalbuminuria in
normoalbuminuric patients with type 2 diabetes (with or
without hypertension) who are at risk of developing
microalbuminuria due to the presence of one or more
cardiovascular risk factors (Haller et al 2006).
The primary endpoint of this multicenter, multinational
study is the occurrence of microalbuminuria. Patient
recruitment started in 2004 and the clinical phase will last
until 325 events of microalbuminuria have occurred, which
is expected to require a median duration of treatment of 5
years. Secondary endpoints include the occurrence of fatal
and non-fatal cardiovascular events. ROADMAP is an
important study because it has been designed to have
sufficient power to assess whether changes in the onset of
microalbuminuria will translate into reductions in the risk
of cardiovascular and renal disease. The results of this
landmark study are expected to be available around 2012,
and may contribute to the development of new approaches
to the management of patients with diabetes.
Atherosclerotic vascular disease is a major contributor
to myocardial and cerebral infarction and hypertension is a
major risk factor for the development and progression of
atherosclerosis. Studies mentioned earlier, such as those in
animals and in markers of vascular inflammation (the
EUTOPIA study) indicate that agents that inhibit the RAS
such as olmesartan medoxomil may possess
antiatherosclerotic efficacy. This is being investigated in
Multi-centre Olmesartan Atherosclerosis Regression
Evaluation (MORE) study. This multinational, randomized,
double-blind, parallel-group study compares the effects of
olmesartan medoxomil with those of atenolol on
atherosclerosis in middle-aged to older hypertensive patients
with increased cardiovascular risk. The MORE study will
assess changes from baseline to various timepoints
(including 28, 52, and 104 weeks) in carotid artery
intimamedia thickness and plaque volume measured by 3D
ultrasonography. It is hoped that initial results from the
MORE study will be presented in 2006.
Tolerability
As outlined in earlier sections of this review, olmesartan
medoxomil has a consistently excellent tolerability profile.
In a pooled analysis of seven trials, olmesartan medoxomil
(2.5–80 mg/day) had a similar tolerability profile to placebo
(Figure 3), and there were no apparent dose-related trends
(Neutel 2001).
Direct comparison trials have shown that the tolerability
of olmesartan medoxomil was comparable with that of the
other angiotensin II receptor antagonists with which it was
compared (Oparil et al 2001; Brunner et al 2003). Adverse
events that were at least possibly related to treatment were
experienced by 8.2%, 9.3%, 9.0%, and 7.5% of olmesartan
medoxomil, losartan, valsartan, and irbesartan recipients,
respectively, in one of the double-blind trials (Oparil et al
2001; Williams 2001) and 4.1% and 6.5% of olmesartan
medoxomil and candesartan cilexetil recipients in the other
double-blind trial (Brunner et al 2003). In both trials, there
were no serious treatment-related adverse events. The most
common treatment-emergent adverse events were upper
respiratory tract infection (2.7% of olmesartan medoxomil
and losartan recipients, 8.3% of valsartan and 5.5% of
irbesartan recipients) headache (4.0%–5.5%), fatigue
(1.4%–3.3%), back pain (0.7%–3.3%), dizziness (0.7%–
3.4%), and diarrhea (0.7%–3.4%) in one trial (Oparil et al
2001), and headache (1.3% and 2.5% of olmesartan
medoxomil and candesartan cilexetil recipients), increased
γ-glutamyl transferase (1.6% and 1.2%), and
hypertriglyceridemia (0.6% and 1.9%) in the other trial
(Brunner et al 2003).
When compared with calcium channel blockers, the
frequencies of adverse events were similar for all active
treatments, except that recipients of amlodipine and
felodipine had a higher incidence of edema than olmesartan
medoxomil recipients (Stumpe and Ludwig 2002; Chrysant
et al 2003).
Like other angiotensin II receptor antagonists,
olmesartan medoxomil does not appear to be associated with
adverse events such as cough and angioedema, which are
often observed with ACE inhibitors.
Cost effectiveness
A pharmacoeconomic analysis, using efficacy data from the
trial that compared olmesartan medoxomil with losartan,
valsartan, and irbesartan (Oparil et al 2001), has been
performed from the perspective of the managed healthcare
environment in the US (Simons 2003). Only direct medical
expenditures associated with cardiovascular events were
taken into account; these included acute hospitalization,
emergency room visits, doctor visits, outpatient services,
and prescription medicines. Data from the Framingham
Heart study were used to quantify the reductions in the risk
for cardiovascular events, and a managed care database was
used to obtain US costs for treating the consequences ofVascular Health and Risk Management 2006:2(4) 337
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inadequate control of hypertension. Based on incremental
benefits calculated using Framingham models and the
absolute reductions in DBP at 8 weeks from the clinical
trial, treating patients in the studied setting with olmesartan
medoxomil instead of the other three angiotensin II receptor
antagonists may decrease the overall cost of medical care
for patients with uncontrolled hypertension (Table 3).
The results indicated that substantial cost savings were
possible with olmesartan medoxomil. For example, when
compared with valsartan, olmesartan medoxomil reduced
estimated costs over 5 years in a hypothetical cohort of
100 000 patients by $16 231 000 for cardiovascular disease
and $11 955 000 for coronary heart disease. The estimated
reduction in costs with olmesartan medoxomil over 5 years
when compared with losartan was estimated to be
$15 149 000 for cardiovascular disease and $11 107 000 for
coronary heart disease. At the time of the analysis, no price
had been set for olmesartan medoxomil so it was assumed
that the angiotensin II receptor blockers were all the same
price. Olmesartan medoxomil has since been priced lower
than other angiotensin II receptor antagonists in the USA;
therefore the results from this analysis were probably
underestimated.
Discussion
It is now apparent that intensive control of BP reduces the
mortality and morbidity associated with hypertension, and
clear BP goals have been set to guide physicians in their
management of patients with hypertension (Chobanian et
al 2003; ESH–ESC 2003) Although combination therapy
will be required by many high-risk patients to reach BP
targets, the initial use of an effective and well tolerated agent
should improve patient compliance and reduce the number
of steps needed to reach BP control.
Olmesartan medoxomil is a selective angiotensin II type
1 receptor antagonist with proven BP-lowering efficacy. In
a number of clinical trials, the agent generally lowered both
mean DBP and SBP by at least 10 mmHg after treatment
for 8 weeks. Importantly, the majority of patients in clinical
trials achieved target DBP of <90 mmHg (Neutel 2001;
Puchler et al 2001; Chrysant et al 2003) Olmesartan
medoxomil has a rapid onset of action, with significant
Figure 3 Adverse events reported by >1% of patients with hypertension in a meta-analysis of seven randomized clinical trials (Neutel 2001) in which patients with
hypertension randomly were randomized to olmesartan medoxomil (various doses from 2.5mg/day to 80mg/day; n=2540) or placebo (n=555) for 6 to 12 weeks.
Copyright © 2002. Reproduced with permission from Warner GT, Jarvis B. 2002. Olmesartan medoxomil. Drugs, 62:1345-53; discussion, 1354-6.
Abbreviations: CPK, creatine phosphokinase; TG, triglyceride; URT, upper respiratory tract.Vascular Health and Risk Management 2006:2(4) 338
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improvements in efficacy compared with placebo observed
from 2 weeks onwards. The drug is also well tolerated, with
an adverse event profile similar to that of placebo.
A considerable body of data now exists that demonstrates
the BP-lowering efficacy of olmesartan medoxomil. At doses
recommended in the EU, olmesartan medoxomil has been
shown to be significantly more effective, in terms of primary
endpoints of sitting cuff or ambulatory daytime DBP, than
other angiotensin II receptor antagonists (valsartan, losartan,
irbesartan (Oparil et al 2001; Stumpe 2004), and candesartan
cilexetil (Brunner et al 2003) at their respective,
recommended doses. The greater BP reduction seen with
olmesartan may have long term clinical implications since
even small decreases in BP have been associated with
changes in the risk of cardiovascular and cerebrovascular
events. Moreover, because of this improved efficacy, cost
estimates indicate that olmesartan medoxomil may be more
cost effective than valsartan, losartan, and irbesartan
(Simons 2003). Additionally, olmesartan medoxomil has
been shown to be at least as effective as the calcium channel
blockers amlodipine (Chrysant et al 2003) and felodipine
(Stumpe and Ludwig 2002) and the beta-blocker atenolol
(Van Mieghem 2001), and significantly more effective than
the ACE inhibitor captopril at the doses tested (Williams
2001).
Current treatment guidelines emphasize the need to
reduce cardiovascular risk in patients with hypertension.
Patients with hypertension frequently suffer from other
conditions that increase their cardiovascular risk, such as
atherosclerosis. Studies such as the MORE study are helping
to further define the potential benefits of olmesartan
medoxomil in the overall reduction of cardiovascular risk
by investigating its effects in patients with atherosclerosis.
Patients with type 2 diabetes are also at increased risk of
cardiovascular disease and olmesartan medoxomil may
come to play a major role in treating such patients. Treatment
of patients with type 2 diabetes with olmesartan medoxomil
has been shown to reduce renal vascular resistance and
oxidative stress, and increase renal perfusion in addition to
significantly reducing BP (Fliser et al 2005). Such effects
may translate into beneficial long-term renoprotective effects
and this is being investigated in the 5 year ROADMAP study,
which commenced in 2004. This study will assess whether
olmesartan medoxomil can prevent or delay the onset of
microalbuminuria, and whether this translates into protection
against cardiovascular events and renal disease, in patients
with type 2 diabetes. Studies such as MORE and
ROADMAP should help to establish that olmesartan
medoxomil offers benefits in terms of cardiovascular risk
reduction that go beyond BP reduction.
As well as having a good tolerability profile, olmesartan
medoxomil has a low potential for drug interactions, and a
pharmacokinetic profile that allows it to be administered
once daily. Recent studies show that olmesartan medoxomil
produces almost complete 24 h blockade of the RAS. These
factors will make the agent easy to prescribe, and should
aid patient treatment compliance.
In conclusion, olmesartan medoxomil is an effective,
fast-acting, and well tolerated antihypertensive agent that
can be administered once daily. At recommended doses, it
is significantly more effective at reducing BP than several
other agents of its class. Thus, olmesartan medoxomil
Table 3 Cost effectiveness estimates of olmesartan medoxomil versus other angiotensin II receptor antagonists. Estimates are
based on treatment for 5 years in a hypothetical cohort of 100 000 individuals. Incremental benefits (events avoided) were
calculated using Framingham models and the absolute reductions in diastolic blood pressure at 8 weeks in a clinical trial comparing
the four agents (Simons 2003)
Cost of Incremental benefit of using Total incremental economic benefit of
cardiovascular olmesartan medoxomil olmesartan medoxomil 
disease or (events avoided) ($US1000)
accident
avoided ($US)
Versus Versus Versus Versus Versus Versus
losartan valsartan  irbesartan   losartan valsartan  irbesartan 
Cardiovascular disease 25 165 602 645 215 15 149 16 231 5140
Coronary heart disease 29 229 380 409 136 11 107 11 955 3975
Myocardial infarction 16 625 244 271 86 4057 4505 1430
Stroke 13 814 104 126 36 1437 1741 497
Death from cardiovascular disease NA 65 80 12 NA NA NA
Death from coronary heart disease NA 66 80 15 NA NA NA
Abbreviations: NA, not available.Vascular Health and Risk Management 2006:2(4) 339
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represents a good option for the initial intensive treatment
of patients with hypertension.
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